July 21, 2026
2 min watch
Add topic to email alerts
Receive an email when new articles are posted on
Please provide your email address to receive an email when new articles are posted on .
LAS VEGAS — Customized microperimetry helped researchers track geographic atrophy in patients undergoing CTx001 gene therapy, according to a presentation at Clinical Trials at the Summit. Arshad Khanani, MD, MA, FASRS, of Sierra Eye Associates in Reno, Nevada, presented initial findings from the first cohort of patients enrolled in the phase 1/2 Opti-GAIN study. The primary endpoints
July 21, 2026
2 min watch
Add topic to email alerts
Receive an email when new articles are posted on
Please provide your email address to receive an email when new articles are posted on .

MONTREAL — Pegcetacoplan may help slow visual acuity loss in patients with geographic atrophy, according to a study presented at…

LAS VEGAS — In this Healio Video Perspective, Tarek S. Hassan, MD, professor of ophthalmology at Oakland University William…

In this video, Sunir J. Garg, MD, FACS, FASRS, talked about a post hoc analysis of pegcetacoplan clinical trials in geographic…

MONTREAL — In a phase 2b study, an intravitreal gene therapy reduced the treatment burden in patients with neovascular…

DENVER — In a phase 1b trial, subretinal delivery of a human stem cell-derived retinal pigment epithelium yielded visual…

Pegcetacoplan slows photoreceptor and retinal pigment epithelium loss in patients with geographic atrophy only as well as…